

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10029810
	Filing Date		2002-07-09
	First Named Inventor	McDONALD, Thomas L.	
	Art Unit	1641	
	Examiner Name	DO, Pensee T.	
	Attorney Docket Number	P04560US00	

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button.							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10029810
	Filing Date		2002-07-09
	First Named Inventor	McDONALD, Thomas L.	
	Art Unit	1641	
	Examiner Name	DO, Pensee T.	
	Attorney Docket Number	P04560US00	

/P.D./	1	BOWIE, "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science 247:1306-1310 (1990).	<input type="checkbox"/>
/P.D./	2	KLUVE-BECKERMAN, "Nonexpression of the Human Serum Amyloid A Three (SAA3) Gene", DNA and Cell Biology, 10(9):651-661 (1991).	<input type="checkbox"/>
/P.D./	3	McDONALD, "A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein", J. of Immunolog. Methods, 144:149-155 (1991).	<input type="checkbox"/>
/P.D./	4	PEDERSEN, "The biology of eukaryotic promoter prediction-a review", Computers & Chemistry 23:191-207 (1999).	<input type="checkbox"/>
/P.D./	5	SACK, "The human serum amyloid A (SAA)-encoding gene GSAA1:nucleotide sequence and possible autocrine-collagenase-inducer function", "Gene, 84:509-515 (1989).	<input type="checkbox"/>
/P.D./	6	SKOLNICK, "From Genes to Protein Structure and Function: Novel Applications for Computational Approaches in the Genomic Area", TIBTECH 18:34-39 (2000).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10069810
	Filing Date		2002-07-09
	First Named Inventor	McDONALD, Thomas L.	
	Art Unit	1641	
	Examiner Name	DO, Pensee T.	
	Attorney Docket Number	P04560US00	

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S.PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button.							Add	
NON-PATENT LITERATURE DOCUMENTS							Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10069810
	Filing Date		2002-07-09
	First Named Inventor	McDONALD, Thomas L.	
	Art Unit	1641	
	Examiner Name	DO, Pensee T.	
	Attorney Docket Number	P04560US00	

/P.D./	1	BOWIE, JAMES U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science 247:1306-10 (1990).	<input type="checkbox"/>
/P.D./	2	SKOLNICK, JEFFREY et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", TIBTECH 18:34-39 (2000).	<input type="checkbox"/>


If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.




Form PTO/SA08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
April 2005 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/069,810
		Filing Date	July 9, 2002
		First Named Inventor	McDonald
		Art Unit	1641
		Examiner Name	
Sheet 1 of 3	Attorney Docket Number	P04560US0	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/P.D./		US- 4,755,380	07-05-1988	Grubb	
		US- 4,952,496	08-28-1990	Studier	
		US- 5,227,302	07-13-93	Turner	
		US- 5,853,985	12-29-1998	Salbaum	
		US- 5,952,313	09-14-1999	Carlson	
		US- 5,958,883	09-28-1999	Snow	
		US- 6,004,936	12-21-1999	Kisilevsky	
		US- 6,013,857	01-11-2000	Deboer	
/P.D./		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)						
/P.D./		EP 0 872 558 A		10-21-1998	Eiken Chemical			
		EP 1 067 194		01-10-2001	F. Hoffmann-La Roche Ag			
		WO/95/21625		08-17-1995	Genzyme Corp			
		WO/97/04317		02-06-1997	The Provost, Fellow & Scholars			
		WO/97/06184		02-20-1997	Eiken Chemical			
		WO/98/03206		01-29-1998	University of Maryland			
		WO/98/40506		09-17-1998	Boehringer Mannheim GmbH			
		WO/99/18227		04-15-1999	Advanced R & T Institute			
		WO/01/14580		03-01-2001	McDonald (Accuplex)			
	/P.D./		WO/01/31006		03-05-2001	Board of Regents Univ of Nebraska		


Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/069,810
		Filing Date	July 9, 2002
		First Named Inventor	McDonald
		Group Art Unit	1641
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	P04560US0	


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/P.D./		BAUMAN et al., "The acute phase response", IT Review, 1994 Elsevier Science Ltd, 0167-5699/94	
		BENSON et al., "A unique insertion in the primary structure of bovine amyloid AA protein", J. Lab Clin Med, vol. 113, pages 67-72, 1989.	
		HULTEN et al., "The acute phase serum amyloid A protein (SAA) in the horse: isolation and characterization of three isoforms", Veterinary Immunology and Immunopathology 57, 215-227, 1997.	
		JENSEN et al., "Regulation of serum amyloid A protein expression during the acute-phase response", Biochem J. 334, 489-503, 1998.	
		KHO et al., GenBank Submission AAF77630, serum amyloid A protein, (Bos Taurus).	
		KHO et al., "Rapid Communication: Cloning of bovine serum amyloid A# cDNA1, American Society of Animal Science, 5-19-2000.	
		KHO et al., "Cloning and characterization of involution-specific genes from the bovine mammary gland" DATABASE EMBL 'Online' Database accession no. AF160867; June 30, 2000.	
		KLUVE-BECKERMAN et al., "Human serum amyloid A - Three Hepatic mRNAs and the corresponding proteins in one person", The Journal of Clinical Investigation, vol 82, pp 1670-1675, 1988.	
		KLUVE-BECKERMAN et al., "Primary structures of dog and cat amyloid A proteins: comparison to Human AA", Comp. Biochem Physiol. B, vol. 94, pages 175-183, 1989.	
		KLUVE-BECKERMAN et al., "Sequence Analysis of a Third Human SAA gene", Database CAPLUS on STN, meeting abstract, 1991.	
		LARSON et al., "Human serum amyloid A3 peptide enhances intestinal MUC3 expression and inhibits EPEC adherence", pgs 531-540, Biochemical and Biophysical Research Communications 300, Elsevier Science, 2002.	
		LARSON et al., "Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide", pgs. 1030-1037, Biochemical and Biophysical Research Communications 301, Elsevier Science, 2003.	
		LIANG et al., "Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells", Journal of Lipid Research 37:2109-2116, 1996.	
		LIEPNIEKS et al., "The primary structure of serum amyloid A protein in the rabbit: Comparison with serum amyloid A proteins in other species", J Lab Clin Med, 118(6):570-576, 1991.	
		MCDONALD et al., "Elevated extrahepatic expression and secretion of mammary-associate serum amyloid A3 (M-SAA3) into colostrums", Veterinary Immunology and Immunopathology 6528, 2001.	
		MALLE, E., "Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice", European Journal of Clinical Investigation 26:427-435, 1996.	
		MARHAUG et al., "Mink serum amyloid A protein. Expression and primary structure based on cDNA", J. Biol. Chem., vol. 265, 10049-10054, 1990.	
/P.D./		MIGITA, K., et al., "Serum Amyloid A Protein Induces Production of Matrix Metalloproteinases by Human Synovial Fibroblasts", Laboratory Investigation, 78(5): 535-539, 1998.	

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
		Application Number	10/069,810
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	July 9, 2002
		First Named Inventor	McDonald
		Group Art Unit	1641
		Examiner Name	
		Attorney Docket Number	P04560US0
Sheet	3	of	3

/P.D./	MITCHELL et al., "Serum Amyloid A SAA3 produced by rabbit synovial fibroblasts treated with phorbol esters or interleukin 1 induces synthesis of collagenase and is neutralized with specific antiserum", Journal of Clinical Investigation, vol. 87, no. 4, pgs 1177-1185, XP000992756, 1991.	
	MITCHELL et al., "The acute phase reactant serum amyloid A (SAA3) is a novel substrate for degradation by the metalloproteinases collagenase and stromelysin", Biochem et Biophysica Acta., 1156:245-254, 1993.	
	PATEL, H., "Human Serum Amyloid A has Cytokine-like Properties", Scand. J. Immunol., 48:410-418, 1998.	
	PERISTERIS, P., "Effects of serum amyloid A protein on lymphocytes, HeLa, and MRC5 cells in culture", Biochem. Cell Biol. 67:365-370, 1989.	
	ROSSEVATN, et al., "The complete amino acid sequence of bovine serum amyloid protein A (SAA) and of subspecies of the tissue-deposited amyloid fibril protein A", Scand. J. Immunol., 35(2), 217-24, 1992.	
	RYGG et al., "In vitro evaluation of an enhanced Human Serum Amyloid A (SAA) Promoter-regulated soluble TNF Receptor Fusion Protein for Anti-Inflammatory Gene Therapy", Scand J Immunol, 2001.	
	SELLAR et al., "Organization of the Region Encompassing the Human Serum Amyloid A (SAA) Gene Famil on Chromosome 11", Genomics, vol. 23, pp. 492-495, 1994.	
	SLETTEN et al., "The amino acid sequence of an amyloid fibril protein AA isolated from the horse", Scand. J. Immunol. 26, 79-84, 1987.	
	SLETTEN et al., "The primary structure of equine serum amyloid A (SAA) protein", Scand. J. Immunol., vol. 30, pages 117-122, 1989.	
	SMITH, J., et al., "Comparison of Serum Amyloid A and C-Reactive Protein as Indicators of Lung Inflammation in Corticosteroid Treated and Non-Corticosteroid Treated Cystic Fibrosis Patients", Journal of Clinical Laboratory Analysis 6:219-224, 1992.	
	SMITH, J. et al., "Use of Ethanol-Eluted Hydrophobic Interaction Chromatography in the Purification of Serum Amyloid A", Protein Expression and Purification 2:158-161, 1991.	
	SMITH, J. et al., "Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone", Clin. Exp. Immunol. 783, 1992.	
	STEEL, et al., "The major acute phase reactant: C-reactive protein, serum amyloid P component and serum and amyloid A protein", Review, Elsevier Science Ltd., 0167-5699/94.	
	STEEL, et al., "Expression and Regulation of Constitutive and Acute Phase Serum Amyloid A mRnas in Hepatic and Non-Hepatic Cell Lines", Blackwell Science Ltd., Scandinavian Journal of Immunology, 44:493-500, 1996.	
	SYVERSEN et al., "The primary structure of serum amyloid A protein in the sheep, comparison with serum amyloid A in other species", Scand. J. Immuno., vol. 39, pages 88-94, 1994.	
	THOMPSON, et al. "The value of acute phase protein measurements in clinical practice, Ann Clin Biochem 29:123-131, 1992.	
	UHLAR, C., "Evolution of the Serum Amyloid A (SAA) Protein Superfamily", Genomics, 19:228-235, 1994.	
▼	WAALEN et al., "The primary structure of amyloid fibril protein AA in endotoxin-induced amyloid", European Journal of Biochem, vol. 104, page 407-412, 1980.	
/P.D./	ZIMLICHMAN, S., "Serum amyloid A, an acute phase protein, inhibits platelet activation, Serum Amyloid A and platelet activation", 116(2):180-186.	

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid and correct number.			
Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/069,810
		Filing Date	July 9, 2002
		First Named Inventor	MCDONALD, Thomas L., et al.
		Art Unit	1641
		Examiner Name	
		Attorney Docket Number	P04560US00
		Sheet	1

[illegible][illegible]

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

on the document under WIPO Standard S.1, 16 if possible.

⁹ Applicant is to place a check mark here if English language Translation is attached.

⁹ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/069,810
				Filing Date	July 9, 2002
				First Named Inventor	MCDONALD, Thomas L., et al.
				Group Art Unit	1641
				Examiner Name	
				Attorney Docket Number	P04560US00
Sheet	2	of	2		

[illegible]

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
-----------------------	-------------	--------------------	------------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

JP43 Rec'd PCT/PTO 25 FEB 2002

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
-----------------------	-------------	--------------------	------------

Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	
		Filing Date	February 25, 2002
		First Named Inventor	Thomas L. McDonald
		Art Unit	
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	P04560US0	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/P.D./		Hirvonen, et al., "Acute Phase Response in Heifers with Experimentally Induced Mastitis", <u>J. of Dairy Res.</u> 63:351-360 (1996)	
↓		Huszenicza, et al., "Diagnostic Value of Certain Mastitis Markers in Following Up the Clinical and Bacteriological Changes in Pharmacotherapeutic Studies", <u>Acta Veterinaria Hungarica</u> 45(4):409-416 (1997)	
		McDonald, et al., "A Monoclonal Antibody Sandwich Immunoassay for Serum Amyloid A (SAA) Protein", <u>J. Immun. Methods</u> 144:149-155 (1991)	
		Satoh, et al., "Sandwich Enzyme-Linked Immunosorbent Assay for Quantitative Measurement of Serum Amyloid A Protein in Horses", <u>Am. J. Vet Res.</u> 56(10):1286-1291	
		Taktak, et al., "A Solid Phase Enzyme Immunoassay for Serum Amyloid A (SAA) Protein", <u>J. Immun. Methods</u> 136:11-16 (1991)	
		Wilkins, et al., "Rapid Automated Enzyme Immunoassay of Serum Amyloid A", <u>Clinical Chemistry</u> 40(7):1284-1290 (1994)	
/P.D./		Zank, et al., "Assessment of Subacute Mammary Inflammation by Soluble Biomarkers in Comparison to Somatic Cell Counts in Quarter Milk Samples from Dairy Cows", <u>J. Vet. Med.</u> 45:41-51 (1998)	

Examiner Signature	/Pensee Do/	Date Considered	09/27/2007
--------------------	-------------	-----------------	------------

* EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.